

- **03.17.23 - Vanda Pharma Appoints Dr. Honoré to its Board ([medtechalert](#))**
 - Dr. Tague Honoré currently President of Aestus Partners a business advisory firm with deep roots in the life sciences sector. Before Vanda, Dr. Honoré held executive leadership roles at Novo Nordisk, Novartis and Purdue Pharma. In addition to his executive accomplishments, Dr. Honoré is a distinguished researcher, credited with discovering and naming the AMPA subtype of Excitatory Amino Acid Receptors, as well as developing the AMPA antagonists CNQX and NBQX, which have played a critical role in advancing scientific understanding in this field. He is also the author of over 100 peer-reviewed scientific articles.
- **03.16.23 - Jubilant HollisterStier Appoints Chris Preti President ([contractpharma](#))**
 - Jubilant HollisterStier (JHS), a U.S.-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products, has appointed Chris Preti as President. He brings more than 25 years of pharmaceutical industry experience in R&D, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President. As previously announced in May 2022, Jubilant HollisterStier's expansion plan is investing approximately \$285 million to double its capacity for fill and finish of sterile injectables at its Spokane, WA facility. The investment is part of the company's cooperative agreement providing \$149.6 million from the U.S. Government to expand its critical vaccine manufacturing capacity in the U.S.
- **ApiJect Appointments of Key Leadership ([PR](#)) - 03.15.23**
 - **Christian Eichhorn, VP, Packaging and Process Development** - Comes from West Pharma where he lead the Containment Expansion R&D team, he focused on the development of new product. As part of West R&D, he founded a new team to expand and centralize analytical engineering capabilities like mold flow simulation and finite element analysis to support rapid development of new container systems. He co-led the creation and rollout of West's Innovation Playbook, an internally developed best practice guide and collection of tools to assist colleagues around the globe apply innovation best practices in their work. **Lauren Shafer Greenberg, VP, Device Development** - Previously with West Pharmaceutical Services, holding increasing levels of responsibilities including, most recently, Director, R&D, Containment Systems. In this and earlier engineering roles, she has led multidisciplinary teams to design and develop elastomeric and polymeric container system components, 510(k) approved medical devices, and device constituents of combination products.
 - **Tony Wasilewski, VP, Pharmaceutical Development Services** - Previously spent 23 years with Fresenius Kabi holding. In his most recent role, he led the newly formed 503B outsourcing business unit where he built a sterile injectable drug portfolio for hospital customers.
- **03.14.23 - Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair ([PR](#))**
 - Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services. Dr. Hubbard was previously the President and CEO of Bioclinica, a leading provider of medical imaging, clinical technology, and development services. Under Dr. Hubbard's leadership, Bioclinica doubled in size, completed several acquisitions, and significantly expanded its customer base before being sold in October 2016. Before his work at Bioclinica, Dr. Hubbard was SVP and Worldwide Head of Development Ops at Pfizer, where he led global clinical operations and development of more than 450 clinical studies per year. He also served as a member of the Portfolio Strategy and Investment Committee, Chair of the Enterprise Precision Medicine Steering Committee, and member of the Worldwide Research and Development Executive Leadership Team. Earlier, he was Group President of ICON plc's Global Clinical Research Services Division.
- **03.14.23 - DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board ([PR](#))**
 - DEM Bio, an immune-oncology company developing therapies that target signals on cancer cells and macrophages to eliminate cancer. Dr. Merad is the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York and the Director of the Mount Sinai Human Immune Monitoring Center, which she founded. Her research over the past 20 years has focused on understanding the mechanisms that control the development and functional identity of dendritic cells and macrophages during homeostasis, and examining how these regulations are changed in cancer and inflammatory diseases. Dr. Merad is credited with identifying the tissue resident macrophage lineage and revealing its distinct role in organ physiology and pathophysiology. She has authored more than 200 primary papers and reviews in high profile journals. Dr. Merad is the recipient of the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology.
- **03.13.23 - TheracosBio Appoints of Jim Greenwood to Board and Jeff McGroarty as CFO ([PR](#))**
 - **Congressman Greenwood** serves as Chair of the DLA Piper Life Sciences Policy and Advocacy Group, in which capacity he advises clients on a variety of legislative, regulatory and policy issues impacting the healthcare and life sciences sectors. He represented the Pennsylvania Eighth Congressional District (mostly now the First Congressional District) from 1993 to 2005 and was a leader on healthcare and the environment. From 2005 to 2020 he served as President and CEO of BIO
 - **Mr. McGroarty** most recently served as CFO of Annovis Bio, a biotech company focused on neurodegenerative disorders, and helped to orchestrate the 2020 IPO of the company. Previously, he spent nearly 13 years in roles of increasing responsibility, culminating in CFO, at Safeguard Scientifics, a capital provider to technology-driven businesses in sectors including healthcare. Mr. McGroarty has also served as VP of Financial Planning and Analysis at Exide Technologies

- 03.13.23 - Abzena bolsters senior leadership team with two key appointments ([PR](#))
 - Abzena, the leading end-to-end integrated CDMO for ADCs and complex biologic molecules, has strengthened its senior leadership team with the appointment of Joe Principe as Chief Commercial Officer, and Matthew Pinkston as Vice President, Program Management.
- 03.09.23 - Allorion Therapeutics Announces Dr. Gregory Berk has officially joined Allorion as the Chief Medical Officer ([PR](#))
 - Before joining Allorion, Dr. Berk held senior management positions as SVP or CMO at several renowned biotech/biopharma companies in the U.S., including Abraxis BioScience, Intellikine, BIND BioSciences, Sideris Pharmaceuticals, and GT Biopharma. His extensive clinical trial experience and industry network will help Allorion transition from preclinical research to the clinical development stage, developing new drugs to address significant unmet medical needs while creating value for the company.
- 03.09.23 - Alcami, a leading CDMO, Promoted Ken Morgan to CFO & appoints Jamie Iudica to Chief Manufacturing Officer ([PR](#))([PR](#))
 - [Ken](#) brings over 25 years of experience in the pharmaceutical industry with considerable experience in finance, mergers, acquisitions, and information system implementations. Ken joined AAI Pharma (now Alcami) in 1997. Before rejoining Alcami, he was the VP and Controller of TriPharm Services, a parenteral contract manufacturing organization acquired by Alcami. After an exceptional 40-year career spanning all facets of the pharmaceutical industry, Alcami Chief Financial Officer Eric Evans has announced his intention to retire in 2023.
 - [Jamie](#) Prior to joining Alcami, Jamie was CMO at Istari Oncology. He has served multiple manufacturing and operations leadership roles throughout his career including executive roles at Xellia Pharmaceuticals, Pfizer, and Hospira.
- 03.08.23 - Biogen names Caroline Dorsa as Papadopoulos successor ([fiercebiotech](#))
 - Less than a month after longtime Biogen Chairman Stelios Papadopoulos, Ph.D., announced his planned retirement, the company has found a successor. Papadopoulos disclosed his plans as he approaches 75, the mandatory retirement age for the company's board. Dorsa takes the lead role after 13 years on the board, a tenure that's included leading the audit committee. Dorsa joined the board in 2010 while she was CFO of New Jersey energy company Public Service Enterprise Group. But she cut her teeth over 21 years at Merck & Co., working different executive positions including SVP of global human health, strategy and integration and treasurer. She's also a board member of Intellia Therapeutics and testing behemoth Illumina.
- 03.10.23 - AskBio, A Bayer Company, Appoints Gustavo Pesquin as CEO ([contractpharma](#))
 - Sheila Mikhail, Co-Founder and the company's first CEO, will transition to a part-time role as Adviser/Co-Founder, and will remain a member of AskBio's Board. Under Mikhail's leadership as CEO since 2017, AskBio has grown to over 800 employees operating in five countries and has advanced six therapeutics through IND, including potential treatments for congestive heart failure, Parkinson's disease, Huntington's disease, multiple system atrophy, Pompe disease and limb-girdle muscular dystrophy type 21/R9. Under her leadership, AskBio built two contract development and manufacturing organization (CDMO) businesses, Viralgen Vector Core SL and TAAV Biomanufacturing Solutions SL. In her new role, Mikhail will continue to support the strategic direction and growth of AskBio. She will also continue to support Columbus Children's Foundation in its development of gene therapies for ultra-rare diseases. In addition to his experience as Chief Commercial Officer at Amneal, Pesquin brings more than 10 years of experience at Sanofi, where he served in leadership roles of increasing responsibility, including North America Head for General Medicines as well as Global Head of the Diabetes and Cardiovascular Franchise. Prior to Sanofi, he held Regional Head, General Manager, Sales Head and Strategy Head roles at Abbott and Pfizer; Brand Management roles at Procter & Gamble; and consultant roles with Boston Consulting Group.
- 03.06.23 - Catalent Appoints Sridhar Krishnan to Lead New Global Operational Excellence Strategy ([Iskh](#))
 - He will also serve on the Executive Leadership Team, reporting directly to Catalent's President & CEO, Alessandro Maselli. The Catalent Way is a company-wide system of continuous improvement with clear standards to enable more predictable and efficient processes. Mr. Krishnan will work alongside senior executives across the company's business segments, and more than 50 global facilities, to implement this strategy. Mr. Krishnan returns to Catalent having spent the previous four years in a number of roles within the pharmaceutical industry, most recently as SVP, Head of Ops, for Jubilant Pharma. He has over 20 years of operational leadership experience within the CDMO space, including as Vice President of Global Operations, and subsequently as Vice President, Global Procurement & Business Analytics at Catalent.
- 03.03.23 - Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma ([Iskh](#))
 - He joins Hansa Biopharma from Pfizer where he has held several senior executive roles, including President, Inflammation and Immunology for the International Developed Markets, President, North America Oncology, and, most recently, SVP responsible for the company's global commercial and medical go-to-market model transformation. Prior to Pfizer, Matthew held roles of increasing responsibility in global strategic marketing and sales leadership, strategic customer group management and licensing and acquisition as well as in product and indication launches across multiple disease areas at Teva, Cephalon, Johnson & Johnson, and Schering-Plough.

- 03.02.23 - Jasper Therapeutics names Vishal Kapoor to board of directors ([mmm-online](#))
 - Kapoor is currently a partner at Avego Management, an affiliate of Velan Capital, where he heads the company's life sciences venture investing strategy. Previously, Kapoor served as president at Amplitude Healthcare Acquisition Corporation, a special purpose acquisition company that focused on life sciences. Amplitude merged with Jasper in September 2021. Jasper is currently putting its bets on its mAb targeting c-Kit (CD117), briquilimab, for treatment of chronic mast and stem cell diseases. Some of those conditions include chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS).

About Berke Search

The Berke Executive Search team is comprised of seasoned and engaged partners who lead our highly specialized firm with an unwavering commitment to excellence and integrity. With over two decades of experience conducting searches for C-Suite, Senior Commercial, Scientific Leadership, and specialized functional leadership disciplines, we have developed deep relationships and a large network of top talent. Our deep experience and expertise benefits clients by shrinking timelines and lowering talent acquisition costs. In addition, our nimble size (boutique) and highly selective client base virtually eliminate conflict of interest and off-limit issues; we execute only a select number of search pools to ensure our resources are maximized and enable superior success rates.

Visit us at Berkesearch.com